Breast Lesion Localization Methods Market is estimated to be valued at USD 461.5 Mn in 2025 and is expected to reach USD 770.7 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.6% from 2025 to 2032.
The global Breast Lesion Localization Methods Market Size boosts with the growing number of breast cancer cases globally and is the primary driver for localization technologies, as precise lesion identification is critical for diagnosis and surgical planning. Increasing prevalence of breast cancer, increasing awareness for treatment, presence of favorable reimbursement policy in developed and emerging economies, and increasing product development are expected to drive growth of the global breast lesion localization methods market.
For instance, in August 2022, Mammotome, a global leader in breast care and the pioneer of vacuum-assisted breast biopsy, unveiled Mammotome Revolve™ EX Dual Vacuum-Assisted Breast Biopsy device.
|
Event |
Description and Impact |
|
Shift Toward Minimally Invasive and Patient-Centric Procedures |
|
|
Regulatory Acceptance and New Device Launches |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of lesion type, the non-palpable Lesions segment is expected to contribute largest share of 35.0% of the market. Non-palpable lesions are the main reason for the use of localization methods. These lesions are increasingly detected through advanced imaging modalities such as mammography, ultrasound, and MRI, often before they become clinically palpable.
For instance, in April 2024, according to recent article published by AME Publishing Company, Breast cancer remains one of the most common malignancies worldwide, contributing 12.5% of the total number of new cases diagnosed in 2020, the latest year available, according to World Cancer Research Fund.
In terms of procedure type, the Wire Localization segment is expected to contribute largest share of the Breast Lesion Localization Methods market trends in 2025, as it is the most commonly used method for guiding the surgical removal of impalpable (nonpalpable) breast lesions, especially in breast-conserving surgery. Its widespread adoption is due to its low cost, ease of use, and proven effectiveness in ensuring accurate lesion excision.
To learn more about this report, Download Free Sample
North America is the largest market for breast lesion localization methods, with a market share of 39% in 2025, which is primarily due to the increasing prevalence of early-stage breast cancer detection through screening mammography in the region. According to the American Cancer Society, approximately 80% of breast cancers are found through mammograms done for routine screening. Screen-detected lesions are often non-palpable as they are too small to be felt by touch alone.
Asia Pacific is the second-largest market for breast lesion localization methods, with a market share of 28.1% in 2025. This is due to the higher prevalence of palpable tumors in the overall breast cancer cases reported from countries such as India, China, and Indonesia. For example, according to article published by the American Cancer Society around 60% of Chinese and 65% of Indonesian women were initially diagnosed with palpable breast lumps.
The U.S. holds a commanding share of the global market, accounting for 78.3% of North America’s market in previous years. The country’s leadership is supported by high procedure volumes, continuous R&D, and a shift toward minimally invasive, patient-friendly techniques. Advanced healthcare infrastructure, high prevalence of breast cancer, rapid adoption of innovative localization technologies for e.g., magnetic seed, radar localization, strong presence of leading companies.
Rising breast cancer cases, growing awareness, expanding access to screening and diagnosis, healthcare infrastructure improvements. India is among the fastest-growing markets due to increasing breast cancer prevalence and government and private initiatives to boost early detection. Adoption of advanced localization methods is accelerating, especially in urban centers, with significant market potential in coming years.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 461.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.6% | 2032 Value Projection: | USD 770.7 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Cook Medical Incorporated, C.R. Bard Inc., Endomagnetics Ltd., SOMATEX Medical Technologies GmbH., Cianna Medical, Argon Medical Devices Inc., Hologic Inc., and STERYLAB. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Increasing incidence of breast cancer has become a major concern globally and is one of the primary factors fueling the growth of the global breast lesion localization methods market. According to recent estimates by World Health Organization (WHO), breast cancer accounts for nearly 12% of all new cancer cases and is one of the leading causes of cancer-related deaths in women worldwide.
It is estimated that over 2 million new cases of breast cancer were diagnosed in 2020 alone. With growing awareness about early detection and diagnosis being critical in improving survival rates, more and more women are opting for various breast cancer screening methods such as magnetic resonance imaging, ultrasound and mammography.
Growing awareness among women about early detection and diagnosis of breast cancer is a major factor boosting the adoption of breast lesion localization methods. Various governments and non-profit organizations around the world have launched several awareness programs to educate women about various screening and diagnostic techniques for breast cancer detection.
For example, organizations like Breast Cancer Foundation and Susan G Komen Foundation conduct regular screening camps and educational sessions that are targeted towards underprivileged sections of the society in developed as well as developing nations.
Adoption of radiofrequency identification (RFID) technology is significantly influencing the breast lesion localization methods market. RFID allows for real-time, wireless tracking of RFID tags or sensors placed within the breast during pre-surgery localization procedures. This provides surgeons with continuous and accurate information on the precise location of lesions during breast cancer excision surgery.
RFID technology offers several advantages over traditional wire or seed-based localization methods. Wire-based localization requires inserting a wire puncture into the breast to mark the location, which can shift before or during surgery and cause inaccurate localization. RFID eliminates the risk of wire displacement.
The integration of imaging capabilities with localization methods is significantly impacting the global breast lesion localization methods market. Techniques such as stereotactic guided biopsy that combines digital mammography or ultrasound imaging with computer assistance for precise needle placement in the breast has seen rising demand.
This allows real-time ultrasound imaging to help navigate the needle to the targeted lesion. It provides surgeons clear views of the breast tissue and lesions for accurate sampling with minimally invasive procedures. Similarly, magnetic resonance (MR)-guided breast biopsy is gaining popularity. MR technology produces high-quality images of breast tissue and helps to differentiate between benign and malignant lesions.
Some of the key players in the global Breast Lesion Localization Methods market are Cook Medical Incorporated, C.R. Bard Inc., Endomagnetics Ltd., SOMATEX Medical Technologies GmbH., Cianna Medical, Argon Medical Devices Inc., Hologic Inc., and STERYLAB.
CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 8 years
*Definition: An abnormal growth or lump inside the breast tissue is called a breast lesion. It may be present as a single lump or as a group of lumps that are either malignant (i.e., cancerous) or benign (i.e., non-cancerous). Any change in breast tissue can be extremely distressing. It becomes alarming when from a sudden and intense ache in the breast region; it gradually changes or develops into a cyst or hard lump.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
